iX Biopharma’s wholly-owned subsidiary iX Syrinx has obtained the good manufacturing practice (GMP) licence issued by the Therapeutic Goods Administration (TGA) of Australia for its testing laboratory in the state of Victoria on September 28.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply